Non-Fatal Overdose Biosurveillance: Building a New Overdose Surveillance Infrastructure

Friday, April 5, 2024

10:30 AM – 11:45 AM

Presenter(s)

EK

Ewa King, PhD

Chief Program Officer
Association of Public Health Laboratories, Maryland

Slides
Charles McKay, Jr., MD, FACMT

Associate Medical Director
Connecticut Poison Control Center, Connecticut
JW

Jill S. Warrington, MD, PhD

Director of Population Health
Department of Pathology and Laboratory Medicine, Vermont
AS

Amanda J. Smith, MPH

Epidemiologist
Centers for Disease Control and Prevention, Georgia

Slides

Non-presenting author(s)

Kelsey E. Granger, MHS

Specialist, Environmental Health
Association of Public Health Laboratories, Maryland
JL

Jennifer Liebreich, MPH

Manager, Environmental Health
Association of Public Health Laboratories (APHL), Maryland

To provide participants with a robust understanding of biosurveillance and current infrastructure being built, this session features a general overview of biosurveillance, provides state-specific and national perspectives, emphasizes the clinical value of biosurveillance, and highlights the various aspects of biosurveillance program implementation, including partner collaboration and program development.

Learning Objectives:

Learners will be able to:

Discuss the value and utility of biosurveillance programs and data across public health, medical, and addiction treatment disciplines
Differentiate biosurveillance programs from other public health and overdose surveillance activities
Explain the benefits of using public-facing dashboards to communicate biosurveillance data to partners and general public